Cabaletta Bio is a clinical-stage biotechnology company developing engineered T-cell therapies for autoimmune disease. Its approach centers on chimeric autoantibody receptor (CAAR) T cells designed to selectively target B cells that produce disease-causing autoantibodies. The pipeline focuses on serious B cell–mediated conditions rather than broad immunosuppression.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -45.1 | — |
| Q3 2025 | 0 | — | -44.9 | — |
| Q4 2025 | 0 | — | -41.9 | — |
| Q1 2026 | 0 | — | -43.5 | — |
| Q2 2026 | 0 | — | -51 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: FB Bancorp, Inc. (FBLA), Melar Acquisition Corp. I (MACI), Cue Biopharma, Inc. (CUE), NewHold Investment Corp III (NHIC), Chicago Atlantic Real Estate Finance, Inc. (REFI), Tailwind 2.0 Acquisition Corp. (TDWD)